Present

Antag Therapeutics to current knowledge on AT7687, its first-in-class GIPR antagonist peptide on the American Diabetes Affiliation’s 2026 Scientific Periods
Press Releases

Antag Therapeutics to current knowledge on AT7687, its first-in-class GIPR antagonist peptide on the American Diabetes Affiliation’s 2026 Scientific Periods

Nova Minerals CEO to Current on the Rising Progress Convention
Press Releases

Nova Minerals CEO to Current on the Rising Progress Convention